Crystal Research Update Highlights 100% Responders Rate in Mild to Moderate COVID-19 Trial Trial meets endpoints in safety and efficacyIND Letter from the CDSCO to optimize dosageEstablishment of an Indian Subsidiary to commercialize ProLectin-M BOSTON, MASSACHUSETTS, Dec. 28,...